Teva Faces More Generic Copaxone Competition From Anticipated Momenta/Novartis Approval
We don’t anticipate changes to our fair value estimates or moat ratings for Teva or Momenta following the U.S. Food and Drug Administration's approval of Momenta’s (through its partner Novartis) 40 mg version of Copaxone. Given Momenta’s previous approval of the 20 mg version, we anticipated this approval following resolution of the regulatory holdup from one of Pfizer’s contract manufacturing sites. This announcement comes slightly earlier than Teva’s estimate of additional Copaxone competition...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.